Skip to main content

Table 1 Characteristics of breast cancer patients

From: Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer

Patient Age (y) Menopause status Histologic type Histological grading B classification MIB-1 (%) Receptor status Molecular subtype
     ER PR HER2  
1 75 Post IDC 2 5b 10 + + Luminal A
2 65 Post IDC 2 5b 10 + + Luminal A
3 54 n.s. IDC 3 5b n.s. n.s. n.s. n.s. n.s.
4 39 Pre IDC 2 5b 40 + + + Luminal B
5 66 Post IDC 2 5b 60 + + Luminal A
6 50 Pre IDC 3 5b 50 + + + Luminal B
7 73 Post IDC 3 5b 20 + + Luminal A
8 76 Post IDC 2 5b 20 + + Luminal A
9 63 Post IDC 3 5 30 + + Luminal A
10 48 Post IDC 3 5b 20 + + + Luminal B
11 58 Post IDC n.s. 5c 20 + + + Luminal B
12 61 Post IDC 3 5b 70 Triple negative
13 52 Pre ILC n.s. 5b 50 + + Luminal A
14 42 Pre IDC 3 5b 80 + Luminal A
15 67 Post IDC 3 5b 40 + + Luminal A
16 61 Post ILC 2 5b 30 + + Luminal A
17 41 Pre Mucinous 2 5b 50 + + + Luminal B
  1. MIB-1 mindbomb E3 ubiquitin protein ligase 1, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, n.s. not specified